Lupin Limited (LUPIN) — Announcement | 24 August 2026

24 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Lupin receives independent ESG rating of 60 from ESG Risk Assessments & Insights Limited

💡 Investor Takeaway

The ESG rating reflects Lupin's current sustainability standing but does not guarantee future performance improvements.

Lupin Limited disclosed an independent ESG rating of 60 from ESG Risk Assessments & Insights Limited, placing it in the 'Adequate' category under SEBI's Regulation 30 disclosure requirements. The rating was self-assigned using publicly available data without external engagement. This regulatory filing highlights Lupin's ESG performance transparency for investors tracking sustainability metrics.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹94,274.49 CrP/E: 16.6ROE: 24.6%ROCE: 27.9%Div Yield: 0.87%

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How does Lupin's ESG rating of 60 compare to industry peers?""What specific metrics contributed to the 'Adequate' category placement?""Will Lupin engage with ESG assessors for future rating updates?"

Ask AI Free →

📊 More LUPIN filings

🔴 Announcement — 28 September 2026Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral s...
Announcement — 28 September 2026Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut u...
🔴 Corporate Action — 21 September 2026Lupin announced on September 21, 2026, the allotment of 24,111 fully paid-up equity shares of ₹2 eac...
🔴 Announcement — 8 September 2026Lupin Ltd announced its participation in two upcoming investor events: the Kotak Healthcare Conferen...
🔴 Announcement — 4 September 2026Lupin announced that the U.S. FDA approved its ANDA for Modafinil Tablets USP 100 mg and 200 mg, mar...

See all LUPIN filings →

🔥 Also filed on 24 August 2026

BALAJITELEBalaji Telefilms LimitedCorporate Action PATINTLOGPatel Integrated Logistics LimitedCorporate Action SKILSKIL Infrastructure LimitedAnnouncement RHLRobust Hotels LimitedAnnual Report AAVASAavas Financiers LimitedAnnual Report CTECambridge Technology Enterprises LimitedAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.